Staff turnover in EUR489.540513.576580.922631.843651.038
Staff turnover in EUR489.540513.576580.922631.843651.038
Die Aktie: Angaben in EURO20212022202320242025
Aktien im Umlauf (in Mio.)820,95823,43694,361.830,55606,86
Dividende pro Aktie2.07942.161412.274153.166613.38289
unverwässertes Ergebnis pro Aktie9,793,056,435,215,99
GuV in Mio. EURO nach IAS/IFRS20212022202320242025
Umsatz47.199,948.273,840.834,744.312,545.288,1
Operatives Ergebnis (EBIT)11.510,89.338,79.125,413.485,215.437,7
Ergebnis vor Steuer (EBT)9.872,28.003,48.210,112.045,813.590,1
Annual net profit/ loss21.961,66.642,57.699,610.516,111.613,5
Bilanz in Mio. EURO nach IAS/IFRS20212022202320242025
Aktiva
Summe Umlaufvermögen41.656,034.149,125.654,326.919,224.131,9
Summe Anlagevermögen82.154,878.507,861.729,169.834,767.427,6
Summe Aktiva123.810,7112.657,087.383,596.754,091.559,5
Passiva
Summe kurzfristige Verbindlichkeiten27.524,026.512,522.211,126.002,121.611,0
Summe langfristige Verbindlichkeiten34.490,731.166,325.825,230.762,733.070,1
Summe Rückstellungen4.279,73.079,12.802,72.749,62.516,2
Summe Eigenkapital61.796,054.978,239.347,139.989,236.878,4
Summe Passiva123.810,7112.657,087.383,596.754,091.559,5
Management:
Vasant (Vas) Narasimhan
Klaus Moosmayer
Steffen Lang
Aharon Gal
Fiona H. Marshall
Harry Kirsch
Karen Hale
Kees Roks
Lutz Hegemann
Michelle Weese
Patrick Horber
Rob Kowalski
Shreeram Aradhye
Victor Bulto
Aufsichtsrat:
Charles Swanton
Elizabeth McNally
Nancy Andrews
Simon Moroney
Ana de Pro Gonzalo
Bridgette Heller
Frans van Houten
John Young
Mary Elizabeth Doherty
Patrice Bula
Ton Büchner
Giovanni Caforio
Aktionärsstruktur in %:
BlackRock Advisors (UK) Ltd. 1,17
BlackRock Asset Management Deutschland AG 0,87
BlackRock Fund Advisors 2,09
Geode Capital Management LLC 1,23
Norges Bank Investment Management 2,28
Novartis AG 10,04
Sandoz Family Foundation 2,08
UBS Asset Management Switzerland AG 6,86
Vanguard Capital Management LLC 3,08
Zürcher Kantonalbank (Investment Management) 1,43
Streubesitz 68,89
Adresse: Lichtstrasse 35, 4056 Basel
T: +41-61-324-11-11
F: +
I: http://www.novartis.com
E: